These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Zhang Y; Qu Z; Kim S; Shi V; Liao B; Kraft P; Bandaru R; Wu Y; Greenberger LM; Horak ID Gene Ther; 2011 Apr; 18(4):326-33. PubMed ID: 21179173 [TBL] [Abstract][Full Text] [Related]
44. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Sapra P; Wang M; Bandaru R; Zhao H; Greenberger LM; Horak ID Nucleosides Nucleotides Nucleic Acids; 2010 Feb; 29(2):97-112. PubMed ID: 20391197 [TBL] [Abstract][Full Text] [Related]
46. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
47. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. Xu L; Anchordoquy T J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003 [TBL] [Abstract][Full Text] [Related]
48. Overview of targeted therapies for cancer. Finley RS Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S4-10. PubMed ID: 14717022 [TBL] [Abstract][Full Text] [Related]
49. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma. Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597 [TBL] [Abstract][Full Text] [Related]
50. Recent advances in the stereocontrolled synthesis of antisense phosphorothioates. Lu Y Mini Rev Med Chem; 2006 Mar; 6(3):319-30. PubMed ID: 16515471 [TBL] [Abstract][Full Text] [Related]
51. Clinical studies of antisense therapy in cancer. Yuen AR; Sikic BI Front Biosci; 2000 Jun; 5():D588-93. PubMed ID: 10833467 [TBL] [Abstract][Full Text] [Related]
53. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Jepsen JS; Pfundheller HM; Lykkesfeldt AE Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077 [TBL] [Abstract][Full Text] [Related]
54. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Barata P; Sood AK; Hong DS Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280 [TBL] [Abstract][Full Text] [Related]
55. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840 [TBL] [Abstract][Full Text] [Related]
56. Targeting the Bcl-2 family in cancer therapy. Papadopoulos K Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799 [TBL] [Abstract][Full Text] [Related]